Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session ...

Hikma Pharmaceuticals PLC closed 11.86% below its 52-week high of £23.60, which the company reached on February 13th.

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

In a report released yesterday, Victoria Lambert from Berenberg Bank maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a price target of p2,560.00. The company’s shares ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Hikma Pharmaceuticals PLC (LON:HIK) is about to go ex ...

JPMorgan Chase & Co. restated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Friday morning, Marketbeat.com reports. Separately, Berenberg ...

Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion (JT file) AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

(Alliance News) - Hikma Pharmaceuticals PLC on Wednesday said it planned to increased spending on research and development to support further growth after reporting strong annual results.